Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of doravirine + islatravir versus bictegravir/emtricitabine/tenofovir alafenamide in treatment-naive adults with HIV-1
PACTR202403575006415Phase 3Recruiting
- Sponsor
- MSD
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing Doravirine + islatravir with Bictegravir + emtricitabine + tenofovir alafenamide (2 arms). Primary endpoints: Percentage of participants with HIV-1 RNA <50 copies/mL and Percentage of participants who experience adverse events and percentage of participants who discontinue study intervention due to adverse events. Started Mar 2023; status: recruiting.
02
Drugs
doravirineislatravirbictegraviremtricitabinetenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on PACTR202403575006415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202403575006415.